DOCSLIB.ORG

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Medication-Assisted Treatment For Opioid Addiction in Opioid Treatment Programs A Treatment Improvement Protocol TIP 43 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment MEDICATION- www.samhsa.gov ASSISTED TREATMENT Medication-Assisted Treatment For Opioid Addiction in Opioid Treatment Programs Steven L. Batki, M.D. Consensus Panel Chair Janice F. Kauffman, R.N., M.P.H., LADC, CAS Consensus Panel Co-Chair Ira Marion, M.A. Consensus Panel Co-Chair Mark W. Parrino, M.P.A. Consensus Panel Co-Chair George E. Woody, M.D. Consensus Panel Co-Chair A Treatment Improvement Protocol TIP 43 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment 1 Choke Cherry Road Rockville, MD 20857 Acknowledgments The guidelines in this document should not be considered substitutes for individualized client Numerous people contributed to the care and treatment decisions. development of this Treatment Improvement Protocol (see pp. xi and xiii as well as Appendixes E and F). This publication was Public Domain Notice produced by Johnson, Bassin & Shaw, Inc. All materials appearing in this volume except (JBS), under the Knowledge Application those taken directly from copyrighted sources Program (KAP) contract numbers 270-99- are in the public domain and may be reproduced 7072 and 270-04-7049 with the Substance or copied without permission from SAMHSA/ Abuse and Mental Health Services CSAT or the authors. Do not reproduce or Administration (SAMHSA), U.S. Department distribute this publication for a fee without of Health and Human Services (DHHS). specific, written authorization from SAMHSAís Christina Currier served as the Center for Office of Communications. Substance Abuse Treatment (CSAT) Government Project Officer, and Andrea Kopstein, Ph.D., M.P.H., served as Deputy Electronic Access and Copies Government Project Officer. Robert Lubran, of Publication M.S., M.P.A., and Alan Trachtenberg, M.D., served as CSAT technical experts. Lynne Copies may be obtained free of charge from McArthur, M.A., A.M.L.S., served as SAMHSAís National Clearinghouse for Alcohol the JBS KAP Executive Project Co-Director. and Drug Information (NCADI), (800) 729-6686 Barbara Fink, R.N., M.P.H., served as or (301) 468-2600; TDD (for hearing impaired), the JBS KAP Managing Project Co-Director. (800) 487-4889; or electronically through the Other JBS KAP personnel included Dennis following Internet World Wide Web site: Burke, M.S., M.A., Deputy Director for www.ncadi.samhsa.gov. Product Development; Wendy Caron, Editorial Quality Assurance Manager; Recommended Citation Frances Nebesky, M.A., Quality Assurance Editor; Leah Bogdan, Junior Editor; Emily Center for Substance Abuse Treatment. Tinkler, Junior Writer; and Pamela Frazier, Medication-Assisted Treatment for Opioid Document Production Specialist. Catalina Addiction in Opioid Treatment Programs. Vallejos Bartlett, M.A., Margaret Brooks, Treatment Improvement Protocol (TIP) Series J.D., Jonathan Max Gilbert, M.A., Randi 43. DHHS Publication No. (SMA) 05-4048. Henderson, and Deborah J. Shuman Rockville, MD: Substance Abuse and Mental were writers. Health Services Administration, 2005. Disclaimer Originating Office The opinions expressed herein are the views Practice Improvement Branch, Division of of the consensus panel members and do not Services Improvement, Center for Substance necessarily reflect the official position of CSAT, Abuse Treatment, Substance Abuse and Mental SAMHSA, or DHHS. No official support of or Health Services Administration, 1 Choke endorsement by CSAT, SAMHSA, or DHHS Cherry Road, Rockville, MD 20857. for these opinions or for particular instruments, DHHS Publication No. (SMA) 05-4048 software, or resources described in this document is intended or should be inferred. Printed 2005 Contents What Is a TIP? ............................................................................................................ix Consensus Panel ..........................................................................................................xi KAP Expert Panel and Federal Government Participants ..................................................xiii Foreword ...................................................................................................................xv Executive Summary ...................................................................................................xvii Chapter 1óIntroduction ...............................................................................................1 Purpose of This TIP .......................................................................................................1 Key Definitions..............................................................................................................2 Audience for This TIP.....................................................................................................2 A Decade of Change........................................................................................................2 Remaining Challenges......................................................................................................6 The Future of MAT .......................................................................................................10 Chapter 2óHistory of Medication-Assisted Treatment for Opioid Addiction...........................11 Emergence of Opioid Addiction as a Significant Problem and the Roots of Controversy .................11 Origins of Opioid Maintenance Therapy .............................................................................17 Regulatory History........................................................................................................21 Chapter 3óPharmacology of Medications Used To Treat Opioid Addiction ...........................25 Pharmacology and Pharmacotherapy ................................................................................28 Dosage Forms ..............................................................................................................31 Efficacy......................................................................................................................32 Side Effects .................................................................................................................33 Interactions With Other Therapeutic Medications.................................................................36 Safety ........................................................................................................................42 Chapter 4óInitial Screening, Admission Procedures, and Assessment Techniques ..................43 Initial Screening ...........................................................................................................43 Admission Procedures and Initial Evaluation ......................................................................46 Medical Assessment .......................................................................................................49 Induction Assessment ....................................................................................................53 Comprehensive Assessment .............................................................................................53 Appendix 4-A. Example of Standard Consent to Opioid Maintenance Treatment ..........................61 iii Chapter 5óClinical Pharmacotherapy ............................................................................63 Contraindications to Opioid Pharmacotherapy ....................................................................64 Stages of Pharmacotherapy.............................................................................................65 Medically Supervised Withdrawal ....................................................................................78 Take-Home Medications ................................................................................................81 Office-Based Opioid Therapy...........................................................................................85 Chapter 6óPatientñTreatment Matching: Types of Services and Levels of Care ..........................................................................87 Steps in PatientñTreatment Matching ................................................................................88 Patients With Special Needs ............................................................................................91 Treatment Planning.......................................................................................................95 Chapter 7óPhases of Treatment..................................................................................101 Rationale for a Phased-Treatment Approach and Duration ...................................................101 Phases of MAT ...........................................................................................................102 Transition Between Treatment Phases in MAT....................................................................119 Readmission to the OTP ...............................................................................................120 Chapter 8óApproaches to Providing Comprehensive Care and Maximizing Patient Retention .................................................................................121 Core Services .............................................................................................................121
Recommended publications
  • The Motivational Hallo

    The Motivational Hallo

    THEMATIC REVIEW Theotivational motivationalhallo helloMANNERS MATTER PART 3 THE With its empathic style, motivational interviewing seems the ideal way to engage new clients in treatment, a psychological handshake which avoids gripping too tightly yet subtly steers the patient in the intended direction. And often it is, as long as we avoid deploying a mechanical arm. by Mike Ashton of THE MANNERS MATTER SERIES is about how services has been on reinforcing motivation, an amalgam of Thanks to Bill Miller, Jim can encourage clients to stay and do well by the acknowledging a problem, wanting help, and resolv- McCambridge, Dwayne Simpson, 5 Don Dansereau, Gerard Connors, manner in which they offer treatment. Parts one and ing that treatment is the help you need. and John Witton for their comments. two dealt with practical issues like reminders, trans- Once thought of as something the patient either Thanks also to Bill Miller, Janice port and childcare. Even at this level, more is in- did or did not have, motivation is now seen as a fluid Brown, Terri Moyers, Paul Amrhein, John Baer and Damaris Rohsenow volved: respect; treating people as individuals; state of mind susceptible to influence. Of the ways for help with obtaining and conveying concern and caring. to exert this influence, motivational interviewing is interpreting their work. Though they 6 have enriched it, none bear any From here on, relationship issues take centre by far the best known. It qualifies for this review responsibility for the final text. stage. Relegated by medicine
  • Nutritional Interventions for Autism Spectrum Disorder

    Nutritional Interventions for Autism Spectrum Disorder

    Lead Article Nutritional interventions for autism spectrum disorder Downloaded from https://academic.oup.com/nutritionreviews/advance-article-abstract/doi/10.1093/nutrit/nuz092/5687289 by Florida Atlantic University user on 06 January 2020 Elisa Karhu*, Ryan Zukerman*, Rebecca S. Eshraghi, Jeenu Mittal, Richard C. Deth, Ana M. Castejon, Malav Trivedi, Rahul Mittal, and Adrien A. Eshraghi Autism spectrum disorder (ASD) is an increasingly prevalent neurodevelopmental dis- order with considerable clinical heterogeneity. With no cure for the disorder, treat- ments commonly center around speech and behavioral therapies to improve the characteristic social, behavioral, and communicative symptoms of ASD. Gastrointestinal disturbances are commonly encountered comorbidities that are thought to be not only another symptom of ASD but to also play an active role in modulating the expression of social and behavioral symptoms. Therefore, nutritional interventions are used by a majority of those with ASD both with and without clinical supervision to alleviate gastrointestinal and behavioral symptoms. Despite a consider- able interest in dietary interventions, no consensus exists regarding optimal nutritional therapy. Thus, patients and physicians are left to choose from a myriad of dietary pro- tocols. This review, summarizes the state of the current clinical and experimental liter- ature on nutritional interventions for ASD, including gluten-free and casein-free, keto- genic, and specific carbohydrate diets, as well as probiotics, polyunsaturated fatty
  • A Qualitative Assessment of Eating Behaviors in Adults with Autism

    A Qualitative Assessment of Eating Behaviors in Adults with Autism

    Illinois State University ISU ReD: Research and eData Theses and Dissertations 2-21-2015 A Qualitative Assessment Of Eating Behaviors In Adults With Autism Samantha Barbier Illinois State University, [email protected] Follow this and additional works at: https://ir.library.illinoisstate.edu/etd Part of the Human and Clinical Nutrition Commons Recommended Citation Barbier, Samantha, "A Qualitative Assessment Of Eating Behaviors In Adults With Autism" (2015). Theses and Dissertations. 317. https://ir.library.illinoisstate.edu/etd/317 This Thesis is brought to you for free and open access by ISU ReD: Research and eData. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of ISU ReD: Research and eData. For more information, please contact [email protected]. A QUALITATIVE ASSESSMENT OF EATING BEHAVIORS IN ADULTS WITH AUTISM Samantha J. Barbier 45 Pages May 2015 Diagnosis of autism has increased ten-fold in the last 40 years, and adults with autism remain an underrepresented population in research. The purpose of this study was to qualitatively explore the relationship between eating behaviors and autism using a questionnaire and interviews with adults diagnosed with autism spectrum disorder. Four males aged 22-27 were interviewed with their mothers present and completed the Swedish Eating Assessment for Autism Spectrum Disorders (SWEAA). Interviews were analyzed through the process of open coding, and the questionnaires were analyzed to determine consistent findings between the interview and the SWEAA questionnaire. Participants generally recognized hunger and satiety and were consuming a high carbohydrate, high fat diet low in vegetables. Variety in food choices was highly dependent upon encouragement from family members.
  • Burke Danielle Final Project 4.14.16 -2

    Burke Danielle Final Project 4.14.16 -2

    Integrating family systems into substance use treatment Item Type Other Authors Burke, Danielle M. Download date 07/10/2021 22:11:04 Link to Item http://hdl.handle.net/11122/8035 DocuSign Envelope ID: 22D0C50D-E5D0-47D1-B6D8-920C7825D12F INTEGRATING FAMILY INTO SUBSTANCE USE TREATMENT By Danielle M. Burke * DocuSigned by: Man* WsfliA, RECOMMENDED! V—_ B59EC4405A35447. .. _______________________________ Hilary Wilson, M. A. , DocuSigned by: l/akric &(fyrji 174D4DC2384B4A1... ______________________________ Dr. Valerie Gifford * DocuSigned by: W a-H R .l'h .l'l >5—=S3BE4E3E6248481™ ------------------------------------------------ Dr. Susan Renes, Advisory Committee Chair * DocuSigned by: V a3RF4F3FR94S4fi1__________________________________________________________________ Dr. Susan Renes, Chair School of Education Counseling Program Running Head: FAMILY INTO SUBSTANCE USE TREATMENT 1 Integrating Family Systems into Substance Use Treatment Danielle Burke A Graduate Research Project Submitted to the University of Alaska Fairbanks in Partial Fulfillment of the Requirements of the Degree of Masters of Education, Counseling Presented to Susan Renes, Ph.D. Valerie Gifford, Ph.D. Hilary Wilson, MA, NCSP University of Alaska Fairbanks Fairbanks, AK Spring 2016 INTEGRATING FAMILY INTO SUBSTANCE USE TREATMENT 2 Abstract It is important to understand the powerful influence of loved ones in the recovery process. This influence can help encourage substance users to receive treatment, help them remain engaged in treatment, and allow those being treated to receive understanding from their loved ones they might not have received without this treatment component. Providing effective substance use treatment to families should take different aspects into consideration, including family dynamics, cultural aspects, and using the best treatment methods available. Treatment providers may not know how to incorporate social supports into specific treatment interventions.
  • Treatment of Patients with Substance Use Disorders Second Edition

    Treatment of Patients with Substance Use Disorders Second Edition

    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
  • Efficacy and Safety of Gluten-Free and Casein-Free Diets Proposed in Children Presenting with Pervasive Developmental Disorders (Autism and Related Syndromes)

    Efficacy and Safety of Gluten-Free and Casein-Free Diets Proposed in Children Presenting with Pervasive Developmental Disorders (Autism and Related Syndromes)

    FRENCH FOOD SAFETY AGENCY Efficacy and safety of gluten-free and casein-free diets proposed in children presenting with pervasive developmental disorders (autism and related syndromes) April 2009 1 Chairmanship of the working group Professor Jean-Louis Bresson Scientific coordination Ms. Raphaëlle Ancellin and Ms. Sabine Houdart, under the direction of Professor Irène Margaritis 2 TABLE OF CONTENTS Table of contents ................................................................................................................... 3 Table of illustrations .............................................................................................................. 5 Composition of the working group ......................................................................................... 6 List of abbreviations .............................................................................................................. 7 1 Introduction .................................................................................................................... 8 1.1 Context of request ................................................................................................... 8 1.2 Autism: definition, origin, practical implications ........................................................ 8 1.2.1 Definition of autism and related disorders ......................................................... 8 1.2.2 Origins of autism .............................................................................................. 8 1.1.2.1 Neurobiological
  • Lodico of UR MG Public Comments August 7. 2015

    Lodico of UR MG Public Comments August 7. 2015

    Oral Fluid/Urine Proposed Mandatory Guidelines Federal Register Notices: Summary of Public Comments Presented by Charles LoDico, M.S., F-ABFT Division of Workplace Programs August 7, 2015 Drug Testing Advisory Board Federal Register Notices 2 • HHS published two Federal Register Notices on May 15, 2015 • Proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (URMG); 94 FR 28101 • Proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OFMG); 94 FR 28054 Public Comments 3 • HHS requested public comment on all aspects of the two Notices • Public comments were accepted until July 14, 2015 (60 days) at http://www.regulations.gov • HHS also specifically requested comment on certain items in the URMG and OFMG HHS URMG Specific Comments 4 • Change cutoff for pH adulterated • ≤ 4 and ≥ 11 • Requalification of MROs • Training and re-exam • 5 years after initial re-qualification URMG Public Comments 5 • 123 commenters • 427 comments • This includes comments relevant to urine that were submitted under the oral fluid FRN URMG Commenters 6 • 123 URMG commenters • 104 Individuals • 9 Professional organizations • 2 HHS-certified laboratories • 1 Collection site • 2 Employers • 5 MROs and/or TPAs Professional Organizations 7 • Airlines for America • Air Line Pilots Association, International • Association of Flight Attendants - CWA • American College of Occupational & Environmental Medicine • International Paruresis Association • National Safety Council • National School
  • Statistical Analysis Plan

    Statistical Analysis Plan

    CONFIDENTIAL 2020N435253_00 The GlaxoSmithKline group of companies 206898 Division : Worldwide Development Information Type : Reporting and Analysis Plan (RAP) Title : Reporting and Analysis Plan for 206898: An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men Compound Number : GSK1265744 Effective Date : 22-APR-2019 Description: The purpose of this RAP is to describe the planned analyses and output to be included in the Clinical Study Report for Protocol 206898. This RAP is intended to describe the safety, tolerability, and pharmacokinetic (PK) analyses required for the study. This RAP will be provided to the study team members to convey the content of the Statistical Analysis Complete (SAC) deliverable. Author’s Name and Functional Area: PPD 22-APR-2019 Senior Biostatistician, PPD PPD 22-APR-2019 Pharmacokineticist (Biostatistics, PPD) Approved by: PPD 22-APR-2019 Statistics Leader, GSK PPD 22-APR-2019 Manager Statistics Copyright 2019 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited. 1 CONFIDENTIAL 2020N435253_00 206898 TABLE OF CONTENTS PAGE 1. REPORTING & ANALYSIS PLAN SYNOPSIS.........................................................5 2. SUMMARY OF KEY PROTOCOL INFORMATION ..................................................8 2.1. Changes to the Protocol Defined Statistical Analysis Plan ............................8
  • Toilet Phobia Booklet

    Toilet Phobia Booklet

    National Phobics Society (NPS) Registered Charity No: 1113403 Company Reg. No: 5551121 Tel: 0870 122 2325 www.phobics-society.org.uk 1975 Golden Rail Award breaking the silence 1989 National Whitbread Community Care Award 2002 BT/THA Helpline Worker of the Year Award The Queen’s Award for Voluntary Service 2006 unsung heros The Queen’s Award for Voluntary Service 2006 what is toilet phobia? Toilet Phobia is rarely just one condition. It is a term used to describe a number of overlapping conditions (see diagram below): social what is toilet phobia? 3 phobia agoraphobia paruresis who can be affected? 4 toilet phobia what causes toilet phobia? 5 panic parcopresis does everyone have the same experience? 5 ocd forms of toilet phobia 6-7 real life experiences 8-12 These conditions have one thing in Due to the nature of this common - everyone affected has problem, people are often difficulties around using the toilet. reluctant to admit to the anxiety & fear: understanding the effects 13-14 These difficulties vary but with the condition or to seek help. right support, the problems can Those who do seek help can usually be alleviated, reduced or usually overcome or improve what types of help are available? 15-19 managed. their ability to cope with the problem, even after many The fears around the toilet include: years of difficulty. Seeking help real life experiences 20 • not being able to is the first step to finding real urinate/defecate improvements. success stories 21 • fear of being too far from a toilet • fear of using public toilets • fear that others may be watching your next step 22 or scrutinising/listening glossary 23 2 3 who can be affected? what causes toilet phobia? Almost anyone - Toilet Phobia is Toilet Phobia and overlapping/ not as rare as you may think.
  • Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’S “Signs” of Higher Quality

    Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’S “Signs” of Higher Quality

    RTI Press Research Report ISSN 2378-7902 July 2020 Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’s “Signs” of Higher Quality Tami L. Mark, William N. Dowd, and Carol L. Council RTI Press publication RR-0040-2007 RTI International is an independent, nonprofit research organization dedicated to improving the human condition. The RTI Press mission is to disseminate information about RTI research, analytic tools, and technical expertise to a national and international audience. RTI Press publications are peer-reviewed by at least two independent substantive experts and one or more Press editors. Suggested Citation Mark, T. L., Dowd, W. N., and Council, C.L. (2020). Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’s “Signs” of Higher Quality. RTI Press Publication No. RR-0040-2007. Research Triangle Park, NC: RTI Press. https://doi.org/10.3768/rtipress.2020.rr.0040.2007 This publication is part of the RTI Press Research Report series.. RTI International 3040 East Cornwallis Road ©2020 RTI International. RTI International is a registered trademark and a trade name of Research Triangle PO Box 12194 Institute. The RTI logo is a registered trademark of Research Triangle Institute. Research Triangle Park, NC 27709-2194 USA This work is distributed under the terms of a Creative Commons Attribution- NonCommercial-NoDerivatives 4.0 license (CC BY-NC-ND), a copy of which is Tel: +1.919.541.6000 available at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode E-mail: [email protected] Website: www.rti.org https://doi.org/10.3768/rtipress.2020.rr.0040.2007 www.rti.org/rtipress Contents About the Authors i Acknowledgments ii Abstract ii About the Authors Introduction 1 Tami L.
  • An Exploratory Investigation Into the Potential of Mobile Virtual Reality for the Treatment of Paruresis – a Social Anxiety Disorder J Lewis, a Paul, D Brown

    An Exploratory Investigation Into the Potential of Mobile Virtual Reality for the Treatment of Paruresis – a Social Anxiety Disorder J Lewis, a Paul, D Brown

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Nottingham Trent Institutional Repository (IRep) An Exploratory Investigation into the Potential of Mobile Virtual Reality for the Treatment of Paruresis – a Social Anxiety Disorder J Lewis, A Paul, D Brown Department of Computing, Nottingham Trent University Nottingham UK [email protected] www.ntu.ac.uk ABSTRACT This paper describes the initial exploratory phase of developing a VR intervention designed to alleviate the problems people with Paruresis experience when they need to utilise public toilet facilities. The first phase of the study produced a virtual environment, based upon a public toilet, which would run on the widely available Gear VR or Oculus Go HMD. The purpose of this prototype was to facilitate an informed discussion with a focus group of Paruresis patients, to obtain preliminary conclusions on whether they were interested in such an intervention and whether it offered potential to help alleviate the condition. In partnership with the UK Paruresis Trust the software was reviewed by both potential users and domain specialists. Results showed that the majority of participants reported a stress response to the stimulus of the virtual public toilet, indicating that it could be effective as a platform for graduated exposure therapy. Focus group feedback, and input from domain experts, was utilised as part of a participatory design methodology to guide the priorities for a second phase of development. The exploratory study concluded that this approach offers great potential as a future treatment for people with Paruresis 1. INTRODUCTION Paruresis is a specific type of social anxiety disorder, also known as Shy Bladder Syndrome.
  • Psychological and Functional Disorder Co-Morbidities in Idiopathic Urinary Retention

    Psychological and Functional Disorder Co-Morbidities in Idiopathic Urinary Retention

    Psychological and functional disorder co-morbidities in idiopathic urinary retention: International Consultation on Incontinence Research Society (ICI-RS) 2019 Running title: Psychological and functional disorder co-morbidities in urinary retention Jalesh N. Panicker1, Caroline Selai2, Francois Herve3, Kevin Rademakers4 Roger Dmochowski5, Tufan Tarcan6, Alexander von Gontard7, Desiree Vrijens8 1Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Queen Square Institute of Neurology, London, United Kingdom 2Department of Clinical and Movement Neurosciences and Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Queen Square Institute of Neurology, London, United Kingdom 3 Urology Department, Cliniques Universitaires Saint Luc, Brussels, Belgium 4 Department of Urology, Zuyderland Medical Centre, Sittard/Heerlen, Netherlands 5 Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, USA 6 Department of Urology, Marmara University School of Medicine, Istanbul, Turkey 7Department of Child and Adolescent Psychiatry, Saarland University Hospital, 66121 Homburg, Germany 8Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands Word count: 3250 Key word: Psychological disorders, anxiety, functional neurological symptom disorders, FND, somatization, urinary retention Corresponding author: Jalesh N. Panicker, Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom Email: [email protected] Telephone: +44(0)2034484713 Abstract Aims: Urinary retention occurring in young women is often poorly understood and a cause may not be found in a majority of cases despite an extensive search for urological and neurological causes. Different psychological co- morbidities and functional neurological symptom disorders (FNDs) have been reported in women with idiopathic urinary retention, however these have been poorly explored.